Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Docetaxel-Epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 [human epidermal growth factor receptor-2] Negative Breast Cancer. A Multicenter Phase I-II Study

Next Previous
Trial Profile

Docetaxel-Epirubicin Plus Bevacizumab as First Line Therapy for Patients With Metastatic and HER2 [human epidermal growth factor receptor-2] Negative Breast Cancer. A Multicenter Phase I-II Study

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 18 Sep 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab; Docetaxel; Epirubicin
  • Indications Advanced breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 19 Aug 2010 Biomarkers information updated
  • 18 Aug 2010 Actual end date (Jun 2010) added as reported by ClinicalTrials.gov.
  • 18 Aug 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top